Patents by Inventor Gregory J. Hannon
Gregory J. Hannon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090170098Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.Type: ApplicationFiled: August 20, 2008Publication date: July 2, 2009Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 7550561Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, a novel polypeptide of 16 kDa (hereinafter “p16INK4” or “p16”) can function as an inhibitor of cell cycle progression, and therefore ultimately of cell growth, and that similar to the role of p21 and p53, the p16 protein may function coordinately with the cell cycle regulatory protein, retinoblastoma (Rb).Type: GrantFiled: April 14, 1994Date of Patent: June 23, 2009Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Publication number: 20090082298Abstract: The invention relates to recombinant vectors for inducible and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene. In certain embodiments, the invention relates to the use of Tet (tetracycline)-responsive RNA Polymerase II (Pol II) promoters (e.g., TetON or TetOFF) to direct inducible knockdown in certain cells of an integrated or an endogenous gene, such as p53. The invention also relates to a method for producing transgenic animals (e.g., mice) expressing inducible (such as tetracycline-regulated), reversible, and/or tissue-specific double-stranded RNA molecules that interfere with the expression of a target gene.Type: ApplicationFiled: June 5, 2008Publication date: March 26, 2009Applicant: Cold Spring Harbor LaboratoryInventors: Ross Dickins, Gregory J. Hannon, Scott W. Lowe
-
Publication number: 20090062228Abstract: The invention relates to small single stranded RNAs and analogs thereof (collectively “piRNA” herein), compositions comprising such piRNAs, and their uses in regulating target gene expression or as markers for certain disease states.Type: ApplicationFiled: March 7, 2008Publication date: March 5, 2009Inventors: Gregory J. Hannon, Michelle A. Carmell, Angelique Girard, Alexei Aravin, Julius Brennecke
-
Publication number: 20090022685Abstract: This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations (e.g., in oncogenes and tumor suppressor genes) that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both, preferably by inducible, reversible, and/or tissue specific expression of double-stranded RNA molecules that interfere with the expression of a target gene, and by transplanting the resulting hepatocytes into a recipient non-human animal. The invention further provides a method to treat cancer involving cooperative interactions between a tumor cell senescence program and the innate immune system.Type: ApplicationFiled: August 15, 2007Publication date: January 22, 2009Inventors: Scott W. Lowe, Gregory J. Hannon, Lars Zender, Wen Xue, Ross Dickins
-
Publication number: 20080242622Abstract: This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.Type: ApplicationFiled: March 19, 2008Publication date: October 2, 2008Applicant: Cold Spring Harbor LaboratoryInventors: Scott W. Lowe, Michael Hemann, Gregory J. Hannon, Darren Burgess
-
Publication number: 20080226553Abstract: This invention provides, among other things, methods for performing RNA interference in stem cells and methods for using stem cells in vivo.Type: ApplicationFiled: September 29, 2003Publication date: September 18, 2008Applicant: Cold Spring Harbor LaboratoryInventors: Scott W. Lowe, Michelle A. Carmell, Gregory J. Hannon, Patrick J. Paddison, Jack Zilfou, Jordan Fridman, Michelle A. Carmell, Ross Dickins, Thomas A. Rosenquist, Stephen J. Elledge
-
Patent number: 7425617Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins.Type: GrantFiled: January 30, 1998Date of Patent: September 16, 2008Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Publication number: 20080213861Abstract: The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: ApplicationFiled: August 20, 2007Publication date: September 4, 2008Inventors: Gregory J. Hannon, Patrick J. Paddison, Despina C. Siolas
-
Publication number: 20040259146Abstract: The present invention provides methods of making a population of nucleic acid molecules, wherein each nucleic acid molecule comprises a predetermined nucleic acid sequence, each of said methods comprising the steps of: (a) synthesizing, on a substrate, a population of nucleic acid molecules wherein: i) each synthesized nucleic acid molecule comprises a predetermined nucleic acid sequence; and ii) each synthesized nucleic acid molecule is localized to a defined area of said substrate; (b) harvesting said population of synthesized nucleic acid molecules from said substrate to yield harvested nucleic acid molecules; and (c) introducing said harvested nucleic acid molecules into vector molecules.Type: ApplicationFiled: June 2, 2004Publication date: December 23, 2004Applicants: Rosetta Inpharmatics LLC, Cold Spring Harbor LaboratoryInventors: Stephen H. Friend, Michele A. Cleary, Kristopher A. Kilian, Ernest M. Coffey, Gregory J. Hannon
-
Publication number: 20040086884Abstract: The present invention provides methods for attenuating gene expression in a cell using gene-targeted double stranded RNA (dsRNA). The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited (the “target” gene).Type: ApplicationFiled: January 24, 2003Publication date: May 6, 2004Applicants: Genetica, Inc., Cold Spring Harbor LaboratoryInventors: David H. Beach, Emily Bernstein, Amy Caudy, Scott Hammond, Gregory J. Hannon, Patrick J. Paddison, Douglas Conklin
-
Publication number: 20030100489Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: September 4, 2001Publication date: May 29, 2003Inventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6486131Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: GrantFiled: January 30, 1998Date of Patent: November 26, 2002Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Publication number: 20020082392Abstract: The present invention reldates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: January 30, 1998Publication date: June 27, 2002Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
-
Publication number: 20020025305Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: ApplicationFiled: January 30, 1998Publication date: February 28, 2002Inventors: DAVID H. BEACH, DOUGLAS J. DEMETRICK, MANUEL SERRANO, GREGORY J. HANNON
-
Patent number: 6331390Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).Type: GrantFiled: June 30, 1995Date of Patent: December 18, 2001Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6255071Abstract: The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli. In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.Type: GrantFiled: March 19, 1997Date of Patent: July 3, 2001Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Gregory J. Hannon, Douglas Conklin, Peiqing Sun
-
Patent number: 6211334Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB). Furthermore, the CCR-protein family includes a protein having an apparent molecular weight of 13.5 kDa (hereinafter “p13.5”). The presumptive role of p13.5, like p16 and p15, is in the regulation of the cell-cycle.Type: GrantFiled: November 29, 1994Date of Patent: April 3, 2001Assignee: Cold Spring HarborInventors: David H. Beach, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6043030Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a novel family of cell-cycle regulatory proteins ("CCR-proteins"). As described herein, this family of proteins is characterized by four ankyrin repeats and the ability to bind to a cyclin dependent kinase (CDK). The family includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. Thus, similar to the role of p21 to the p53 checkpoint, the subject CCR-proteins may function coordinately with the cell-cycle regulatory protein, retinoblastoma (RB).Type: GrantFiled: January 2, 1996Date of Patent: March 28, 2000Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 6025192Abstract: The present invention relates to methods and compositions for the elucidation of mammalian gene function. Specifically, the present invention relates to methods and compositions for improved mammalian complementation screening, functional inactivation of specific essential or non-essential mammalian genes, and identification of mammalian genes which are modulated in response to specific stimuli.In particular, the compositions of the present invention include, but are not limited to, replication-deficient retroviral vectors, libraries comprising such vectors, retroviral particles produced by such vectors in conjunction with retroviral packaging cell lines, integrated provirus sequences derived from the retroviral particles of the invention and circularized provirus sequences which have been excised from the integrated provirus sequences of the invention. The compositions of the present invention further include novel retroviral packaging cell lines.Type: GrantFiled: September 20, 1996Date of Patent: February 15, 2000Assignee: Cold Spring Harbor LaboratoryInventors: David Beach, Gregory J. Hannon